Asian Journal of Research and Reports in Urology

Role of Alpha-Blocker, Anti-Cholinergics and Combination Therapy in Treatment of Symptoms Related to DJ Stent

Wesh Ansari *

Department of Urology and Renal Transplantation, Consultant Renal Transplant Surgeon, Sumeru Hospital, Dhapakhel, Lalitpur, Nepal.

Kaish Warish

Department of General Surgery, National Medical College, Birgunj, Nepal.

Shahin Parveen

Department of Ophthalmology, Sumeru Hospital, Nepal.

Khustar Taj Akhtar Noorani

National Medical College, Birgunj, Nepal.

Amit sah

West Palm Beach VA Health Care System, USA.

*Author to whom correspondence should be addressed.

---

Abstract

In routine urological procedure ureteric DJ stents are important and basic tool. The history of DJ stenting is too old, Gustav simon in 1800s performed first DJ stenting following open cystostomy. Following his success, Zimskind et al in 1967 placed DJ stent endoscopically [1]. Later on it flourished as a important tool in endourology. With the passage of time, multiple changes were made in features & structure of DJ stent to ensure a good urinary drainage with lesser complications. In modern age of urology the uses of DJ stent have been expanded.

Ureteric stents are now used in treatment of various diseases related to urinary tract. For example, to prevent ureteric obstruction postoperatively from mucosal oedema, mucosal erosion/damage following uretrorenoscopy for ureteric stone or other upper tract interventions, following ballon dilatation of ureteric stricture, following endopyelotomy / pyeloplasty, to relieve obstruction in pelvic malignancy etc. [2]. DJ stenting is now performed in routine endourological and open surgery for avoidance of ureteric obstruction [3]. Selective alpha blockers / anti- muscarinic are used in alleviating the symptoms due to DJ stent like urgency, frequency of urination and painful micturation.

Objectives: To assess the role of α-blockers(tamsulosin) or anticholinergic(tolterodine) alone and in combination, in the management of DJ related symptoms.

Material and Methods:

Study Design: Randomized control Trial.

Study Setting: Jinnah Hospital Lahore, Pakistan.

Study Duration: Six months – One year.

Data Collection and Analysis: All patients with DJ stent in situ were followed on weekly basis in outpatient department to assess the development of DJ related symptoms. A total of ninety  patients, who developed symptoms during their course of follow up were separated in three groups, group A, B & C, each comprising of 30 patients.  Group A, patients received 0.4 mg tamsulosin daily. Group B,  received 2mg tolterodine twice daily. Group C, received 0.4 mg tamsulosin daily&  2mg tolterodine twice daily. IPSS and VAPS score were compared within and in between groups at enrollment, during each follow up weeks and at the completion of study. The results were  compared between Group A, B (monotherapy) and group C (combination therapy).

Keywords: Urethral stent / DJ stent, anticholinergic, alpha blockers

---

---

---

References

Zimskind PD, Fetter TR, Wilkerson JL. Clinical use of long-term indwelling silicone rubber ureteral splints inserted cystoscopically. J Urol. 1967;97:840– 844.

Chew BH, Lange D, Paterson RF, Hendlin K, Monga M, Clinkscales KW, et al. Next generation biodegradable ureteral stent in a Yucatan pig model. J Urol. 2010; 183:765–771.

Paz A, Amiel GE, Pick N, Moskovitz B, Nativ O, Potasman I, Febrile, et al. Complications following insertion of 100 double-J ureteral stents. J Endourol. 2005;19:147-150.

Finney RP, et al. Experience with new double J ureteral catheter stent. J Urol.1978;167:1135–1138. Discussion 1139.

Cauda F, Cauda V, Fiori C, Onida B, Garrone GF, et al. Heparin coating on ureteral double J stents prevents encrustations: An in Vivo case study. J Endourol. 2008;22(3):465–472.

Nawaz H, Hussain M, Hashmi A., Hussain Z, et al. Experience with indwelling JJ stents. J Pak Med Assoc. 1993;43:147-9.

Jeon SS, Choi YS, Hong JH. Determination of ideal stent length for endourologic surgery. J Endourol. 2007;21:906–910.

Gupta M, Patel T, Xavier K, Maruffo F, Lehman D, Walsh R, et al. Prospective randomized evaluation of periureteralbotulinum toxin type A injection for ureteral stent pain reduction. J Urol. 2010;183:598–602.

Dellis A, Joshi HB, Timoney AG, Keeley FX Jr, et al. Relief of stent related symptoms: Review of engineering and pharmacological solutions. J Urol. 2010; 184:1267–1272.

Kwon JK, Cho KS, Oh CK. The beneficial effect of alpha-blockers for ureteral stent-related discomfort: Systematic review and network meta-analysis for alfuzosin versus tamsulosin versus placebo. BMC Urol. 2015;15:55.

Damiano R, Autorino R, de Sio M, et al. Does the size of ureteral stent impact urinary symptoms and quality of life? A prospective randomized study. European Urology. 2005;48(4):673–678.

Haleblian G, Kijvikai K, de la Rosette J, Preminger G, et al. Ureteral stenting and urinary stone management: A systematic review. J Urol. 2008;179:424–430

El-Faqih SR, Shamsuddin AB, Chakrabarti A, Atassi R, Kardar AH, Osman MK, et al. Polyurethane internal ureteral stents in treatment of stone patients: Morbidity related to indwelling times. J Urol. 1991; 146:1487–1491.

Thomas R, et al. Indwelling ureteral stents: Impact of material and shape on patient comfort. J Endourol.1993;7:137–140.

Joshi HB, Okeke A, Newns N, Keeley FX Jr, Timoney AG. Characterization of urinary symptoms in patients with ureteral stents. J Urology. 2002;59(4):511–516.

Lee SJ, Yoo C, Oh CY, Lee YS, Cho ST, Lee SH, et al. Stent position is more important than alpha-blockers or anticholinergics for stent-related lower urinary tract symptoms after ureteroscopicureterolithotomy: A prospective randomized study. Korean J Urol. 2010;51:636–641.